News

Medigene Receives Further European Patent on EndoTAG®-1

Martinsried/Munich, 29 May 2013. Medigene AG (Frankfurt, Prime Standard; MDG) announced today that the European Patent Office has granted a further patent which protects the drug candidate EndoTAG®-1. The term of the patent EP 2108362 entitled "A cationic liposomal preparation comprising a taxane" ends on June 26, 2023.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG: "The new patent strengthens the patent position for EndoTAG®-1 in Europe. We will continue to extend our patent portfolio to ensure protection of the EndoTAG®-1 product for Medigene and our partner SynCore."

About EndoTAG®-1: The clinical drug candidate EndoTAG®-1 is a novel composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Because of the positively charged lipids, EndoTAG®-1 interacts with newly developed, negatively charged endothelial cells, which are particularly required for the generation of tumor blood vessels. The EndoTAG®-1 paclitaxel component attacks the endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the blood supply to healthy tissue. By doing this, EndoTAG®-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth. Medigene has successfully completed two clinical phase II trials of EndoTAG®-1 in pancreatic cancer and triple-negative breast cancer (TNBC). The drug candidate has also shown positive results in a recently concluded investigator-initiated trial (IIT) in HER2-negative breast cancer.  

Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from a marketed product (Veregen®), which is distributed by partner companies. Medigene has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.